Calcipotriene interactions

Instruct the patient the avoid fire, flame, and smoking during and immediately following application. (Calcipotriene label, Warnings and precautions)

Use of Miacalcin injection for the treatment of Paget’s disease or postmenopausal osteoporosis is recommended in conjunction with an adequate intake of calcium and vitamin D [see Dosage and Administration (2.5) ] . (Calcitonin salmon label, Warnings and precautions)

WARNINGS AND PRECAUTIONS Treat mild hypercalcemia by reducing or interrupting calcium acetate capsules and Vitamin D. (Calcium acetate label, Warnings and precautions)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (Calcium chloride label, Drug interactions)

If corrected serum calcium falls below the lower limit of normal or symptoms of hypocalcemia develop, start or increase calcium supplementation (including calcium, calcium-containing phosphate binders, and/or vitamin D sterols or increases in dialysate calcium concentration). (Cinacalcet label, Warnings and precautions)

Danazol can increase the calcemic response to synthetic vitamin D analogs in primary hypoparathyroidism. (Danazol label, Drug interactions)

Monitor calcium levels during therapy, especially in the first weeks of initiating therapy, and adequately supplement all patients with calcium and vitamin D. (Denosumab label, Warnings and precautions)

Hypercalcemia may be exacerbated by concomitant administration of high doses of calcium-containing preparations, thiazide diuretics, or other vitamin D compounds [see Drug Interactions ( 7 )]. (Doxercalciferol label, Warnings and precautions)

Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (Ferric citrate label, Drug interactions)

Other Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D Drugs whose level is decreased by phenytoin Anticoagulants Apixaban, dabigatran, edoxaban, rivaroxaban Antiepileptic drugs The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels… (Fosphenytoin label, Drug interactions)

Instruct patients to take supplemental calcium and vitamin D if their dietary intake is inadequate (see Dosage and Administration [2.3] ) . (Ibandronate label, Warnings and precautions)

The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (Orlistat label, Drug interactions)

• Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (Pamidronate label, Warnings and precautions)

Hypercalcemia may be exacerbated by concomitant administration of high doses of calcium-containing preparations, thiazide diuretics, or other vitamin D compounds [see Drug Interactions (7) ] . (Paricalcitol label, Warnings and precautions)

Effects on Vitamin D and Bone The chronic use of phenytoin in patients with epilepsy has been associated with decreased bone mineral density (osteopenia, osteoporosis, and osteomalacia) and bone fractures. (Phenytoin label, Warnings and precautions)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (Risedronate label, Drug interactions)

All patients should be instructed about the symptoms of hypocalcemia and the importance of calcium and vitamin D supplementation in maintaining serum calcium levels [see Dosage and Administration ( 2.8 ), Adverse Reactions ( 6.1 ), Patient Counseling Information ( 17 )]. (Zoledronic acid label, Warnings and precautions)

Other disorders affecting mineral metabolism (such as vitamin D deficiency) should also be effectively treated. (Alendronate label, Warnings and precautions)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (Calcium gluconate label, Drug interactions)

Other Medications Used for the Management of Fanconi Syndrome PROCYSBI can be administered with other electrolyte and mineral replacements necessary for management of Fanconi syndrome, as well as vitamin D and thyroid hormone. (Cysteamine label, Drug interactions)

Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher in subjects receiving TDF. (Efavirenz, lamivudine, and tenofovir label, Warnings and precautions)

Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher in subjects receiving TDF. (Emtricitabine, rilpivirine, and tenofovir label, Warnings and precautions)

• Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (Exemestane label, Warnings and precautions)

Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher in subjects receiving VIREAD. (Tenofovir label, Warnings and precautions)